摘要
目的 探讨前列腺特异性抗原密度(PSAD)对良性前列腺增生与前列腺癌的鉴别诊断价值.方法 采集80 名健康人、160例良性前列腺增生患者和60例前列腺癌患者的血清,用化学发光免疫法测定前列腺特异性抗原(PSA),腹部前列腺B超检查计算前列腺体积,计算前列腺特异性抗原密度. 结果前列腺癌患者PSA和PSAD水平分别为(82.66±20.62) μg/L和(0.68±0.2),前列腺癌患者中PSA和PSAD水平明显高于前列腺增生患者. 160例良性前列腺增生患者血清PSA水平为4～10 μg/L,明显高于正常对照组,前列腺癌组中PSA>10 μg/L 和PSAD>0.2明显高于前列腺增生患者.血清PSA>10 μg/L 诊断前列腺癌的敏感性和特异性分别为50.0%和91.3%,PSAD诊断前列腺癌的敏感性和特异性为96.7%和85.0%. 结论 PSAD是诊断前列腺癌更敏感、更有效的指标,在前列腺癌和良性前列腺增生中有鉴别意义.
Objective To study the diagnostic value of prostate specific antigen density PSAD in prostate cancer patients and benign prostatic hyperplasia patients.Methods Collecting the serum samples from 80 health people,160 benign prostatic hyperplasia patients and 60 prostate cancer patients.The serum level of prostate specific antigen(PSA) detected by chemiluminescence.The prostate size measured by ultrasound prostate B,the prostate specific antigen density is calculated.Results The level of PSA and PSAD was(82.66±20.62) μg/L and(0.68±0.2) in prostate cancer patients,respectively.The level of PSA and PSAD in prostate cancer patients significantly increased than that in benign prostatic hyperplasia patients.The level of serum PSA between 4 to 10 μg/L in benign prostatic hyperplasia patients is significantly higher than that in healthy people.The level of PSA>10 μg/l and PSAD>0.2 in prostate cancer patients significantly increased than that in benign prostatic hyperplasia patients.The sensitivity and specificity was 50.0% and 91.3%,respectively,when serum PSA>10 μg/L diagnoses prostate cancer.The sensitivity and specificity was 96.7% and 85.0%,respectively,when serum PSAD diagnoses prostate cancer.Conclusion PSAD is more sensitivity and effect in diagnoses prostate cancer.It has a distinguished value in differentiation of prostate cancer patients from benign prostatic hyperplasia patients.
出处
《临床军医杂志》
CAS
2010年第6期975-976,共2页
Clinical Journal of Medical Officers
